GenoGenix LLC, Raton, FL
Is GenoGenix LLC an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names GenoGenix LLC in Raton, FL, first registered Feb 4, 2025 and most recently registered Feb 11, 2026. FDA lists its last inspection as Jul 18, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Raton, FL
- Initial registration
- Feb 4, 2025
- Most recent registration
- Feb 11, 2026
- Last inspection
- Jul 18, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- N/A
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
No entry for this facility was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). FDA may list it under a different name, and the page covers actions from 2019 on.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
The dashboard does list GenoGenix LLC, Boca Raton, FL (FEI 3032144832): same name and state, different city, so not treated as this site.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA links 1 Form 483 PDF for GenoGenix LLC, but no observation text is shown, for the reasons below.
Linked 483s whose text is not shown
- Jul 18, 2025: FDA document 188559: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
The same legal name appears in 1 GLP-1 warning letter and 4 GLP-1 recall reports in this index. See the GenoGenix LLC record page.
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Jan 20, 2026 | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
| Record | |||||
|---|---|---|---|---|---|
| Jul 30, 2025 | Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as m... | Lack of Assurance of Sterility | Class II | Ongoing | D-0091-2026 |
| Jul 30, 2025 | Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. | Lack of Assurance of Sterility | Class II | Ongoing | D-0083-2026 |
| Jul 30, 2025 | Tirzepatide, 60mg/10 mL for Injection, 10mL vial lyophilized, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labe... | Lack of Assurance of Sterility | Class II | Ongoing | D-0092-2026 |
| Jul 30, 2025 | Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692 | Lack of Assurance of Sterility | Class II | Ongoing | D-0093-2026 |
The GenoGenix LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA warning letter, Jan 20, 2026
Records last pulled Nov 15, 2026. Every entry links to the original public record.